natgillin/translations-raw huggingface dataset:
An antisense oligonucleotide of 22 bases comprising a base sequence that is 100% complementary to 22 consecutive bases of exon 52 of the human dystrophin pre-mRNA, wherein the base sequence comprises 21 consecutive bases of CAGCGGTAATGAGTTCTTCCAACTG (SEQ ID NO:385), in which thymine bases are uracil bases, wherein the antisense oligonucleotide is a 2′-O-methyl oligonucleotide, and wherein the antisense oligonucleotide induces exon 52 skipping; or a pharmaceutically acceptable salt thereof. 
Protusmisleni oligonukleotid koji sadrži 20-35 morfolino podjedinica povezanih s vezama među podjedinicama koje sadrže fosfor koje spajaju morfolino dušik jedne podjedinice sa 5' 'egzocikličkim ugljikom susjedne podjedinice, koji sadrži baznu sekvencu SEQ ID NO: 382, ili sekvencu koja ima s njom barem 80% identičnosti sekvence, pri čemu su timinske baze proizvoljno uracilne baze, te pri čemu je protusmisleni oligonukleotid komplementaran s ljudskim distrofinom pred-mRNA da se inducira preskakanje eksona 52; ili njegova farmaceutski prihvatljiva sol.
Method of producing a semi-product for a building panel, such as a floorboard, wherein the method comprises: 
Postupak proizvodnje poluproizvoda za građevnu ploču, kao što je podna ploča, naznačen time što postupak obuhvaća:
The laser threat warning system according to claim 1, wherein said laser detectors are selected from the list consisting of: 
Sustav upozorenja o laserskoj prijetnji u skladu sa zahtjevom 1, pri čemu navedeni laserski detektori nadalje sadrže:
The bispecific antibody of aspect 9, wherein said H/L chain combination that binds a tumor-antigen binds CLEC12A. 
Bispecifično protutijelo sukladno patentnom zahtjevu 7, naznačeno time, da spomenuta kombinacija H/L lanca koja veže tumorski antigen veže CLECI2A.
The vaccine composition of item 12 wherein the viral vector is selected from the group consisting of an adenovirus vector, an adeno-associated virus vector, a herpesvirus vector, a lentivirus vector, a poxvirus vector and a retrovirus vector. 
10. Pripravak cjepiva u skladu s patentnim zahtjevom 9, naznačen time što se virusni vektor bira iz skupine koju čine adenovirusni vektor, adenoasocirani virusni vektor, herpesvirusni vektor, lentivirusni vektor, poksvirusni vektor 1 retrovirusni vektor.
The invention is directed to a process for the production of urea from ammonia and carbon dioxide in a urea plant containing a synthesis section comprising two reactor sections, a stripper and a condenser, and a recovery section, wherein in the first reactor section a first synthesis solution is formed that is fed to the second reactor section; fresh carbon dioxide is fed to the second reactor section and in the second reactor section a second synthesis solution is formed that is fed to the stripper, wherein the second synthesis solution is stripped with the use of carbon dioxide as stripping gas and the mixed gas stream obtained in the stripper is sent to the condenser together with fresh ammonia and a carbamate stream, whereafter the condensate that is formed in the condenser is fed to the first reactor section and the urea stream that is obtained in the stripper is further purified in a recovery setion. 
HR P20171925 T1 PATENTNI ZAHTJEVI no Postupak za proizvodnju uree od amonijaka i ugljičnog dioksida u postrojenju za proizvodnju uree, a) pri čemu postrojenje za proizvodnju uree sadrži odjeljak za regeneraciju i sekciju za sintezu visokog tlaka koja obuhvaća dva reaktorska odjeljka, ekstrahator i kondenzator, b) pri čemu se u prvom reaktorskom odjeljku stvara prva otopina sinteze koja se dovodi u drugi reaktorski odjeljak; c) svježi ugljični dioksid se dovodi u drugi reaktorski odjeljak i u drugom reaktorskom odjeljku se stvara se druga otopina sinteze koja se dovodi u ekstrahator, d) pri tome se druga otopina sinteze uklanja uporabom ugljičnog dioksida kao plina za uklanjanje, i tok miješanog plina dobiven u ekstrahatoru šalje se kondenzatoru zajedno sa svježim amonijakom i strujom karbamata i kondenzira pod uklanjanjem topline, e) = zatim se kondenzat koji se stvara u kondenzatoru dovodi u prvi reaktorski odjeljak f)
An affinity reagent which is capable of specific binding to Lymphocyte antigen 75 for use in treatment or prophylaxis of lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer, lung cancer, colorectal cancer, kidney cancer or liver cancer. 
PATENTNI ZAHTJEVI Žž, Antitijelo koje je sposobno za specifično vezivanje limfocitnog antigena 75 za uporabu u liječenju raka pankreasa pri čemu spomenuto antitijelo sadrži ili se konjugira na terapijski dio.
a polypeptide comprising the amino acid sequence of the sushi domain of the IL-15Ra, 
polipeptid, koji sadrži aminokiselinski slijed sushi domene IL-15Ra, gdje konjugat ima aminokiselinski slijed SEQ ID NO: 17.
The pharmaceutical combinations according to the invention may contain (a) and (b) in the case of roflumilast, for example, in a ratio by weight (b):(a) ranging from 1:10 to 300:1, preferably from 1: 5 to 200: 1, preferably 1: 3 to 150: 1, more preferably from 1: 2 to 100: 1. 
Farmaceutske kombinacije sukladno predmetnom izumu mogu sadržavati (a) 1 (b) u slučaju formoterola, na primjer u težinskom omjeru (b):(a) u rasponu od 1:10 do 300:1, poželjno od 1:5 do 200:1, poželjno od 1:3 do 150:1, a poželjnije od 1:2 do 100:1.
Aqueous slurry according to one of claims 18 or 19, wherein said surface modified calcium carbonate containing mineral has a BET specific surface area of more than 15 m2/g, and preferably from about 20 m2/g to about 200 m2/g, more preferably from about 30 m2/g to about 150 m2/g, even more preferably from about 40 m2/g to about 100 m2/g. 
HR P20160848 T1 Vodena suspenzija prema jednom od zahtjeva 16 ili 17, naznačena time da navedeni površinski modificirani kalcijev karbonat koji sadrži mineral ima BET specifičnu dodirnu površinu od oko 20 m'/g do oko 200 m'/g, poželjno od oko 30 m"/g do oko 150 m'/g, poželjnije od oko 40 m"/g do oko 100 m/g.
The method of claim 8, wherein the target epitope recognized by the variable regions of the 3rd and 4th CH3 domain antibody heavy chain is different from the target epitope recognized by the variable region of the 1st or the 2nd antibody heavy chain. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što je ciljni epitop kojeg prepoznaju varijabilne regije trećeg i četvrtog polipeptidnog lanca koji sadrži CH3 domenu različitu od ciljnog epitopa kojeg prepoznaje varijabilnu regiju prvog ili drugog polipeptidnog lanca koji sadrži CH3 domenu.
in the presence of a base; or 
NH2 u prisutnosti baze; ili
administering a drug candidate to said rodent; and monitoring the human cells in the rodent to determine the therapeutic efficacy of the drug candidate. 
(b) primjeni kandidatnog lijeka na navedenom glodavcu; i (c) praćenju ljudskih stanica u glodavcu kako bi se odredilo terapijsku djelotvornost kandidatnog lijeka.
Instead of the needle there is a tube which has to be introduced into the uterine cavity. 
Umjesto igle je cijev koja se treba uvesti u šupljinu maternice.
A compound of claim 1 or 2, selected from the group consisting of or a pharmaceutically acceptable salt of any of the foregoing. 
Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koja sadrži:
a first configuration destined for executing said step of positioning the fabric strip around the loading members, wherein said loading elements are placed circumferentially around said second central axis at a distance from the latter corresponding to a first radius; 
– prve konfiguracije, namijenjene provođenju navedenog koraka stavljanja trake od tkanine oko naprava za punjenje, gdje su navedeni elementi za punjenje (35) smješteni po obodu oko navedene druge središnje osi udaljene od potonjeg koji odgovara prvom polumjeru;
In the first step (step i), the compound of formula (IV) is reacted with 1,2-dibromoethane to form a compound of formula (V) wherein X′ is as defined above. 
(IV) u kojoj je X* odabran od sljedećih: klor, brom, jod 1 triflatna skupina (CF3SO:) s 1,2-dibrometanom, pri čemu nastaje spoj formule (V),
The method for preparation of agomelatine using the compound A according to claim 5, characterized in that the solvent used in the reaction is the mixture of toluene and glacial acetic acid, the mixture of acetonitrile and glacial acetic acid, or glacial acetic acid. 
Postupak priprave agomelatina uporabom spoja A u skladu s patentnim zahtjevom 5, naznačen time, da je otapalo koje se koristi u reakciji smjesa toluena i ledene octene kiseline, smjese acetonitrila i ledene octene kiseline ili ledene octene kiseline.
A compound selected from Compound 32 and Compound 33: 
Spoj naznačen time da se bira od spoja 32 i spoja 33:
R2c and R2d are each independently selected from H and optionally substituted C1-C8 alkyl, or together with the nitrogen to which they are attached form an optionally substituted hetero C3-C10 cycloalkyl, wherein said optional substituents are one to three R10 groups; 
c i R2d su svaki nezavisno odabrani od H i proizvoljno supstituiranog C1-C8 alkila, ili zajedno s atomom dušika za kojega su vezani tvore proizvoljno supstituirani hetero C3-C10 cikloalkil, pri čemu su navedeni nezavisni supstituenti jedna do tri R10 skupine;
Appropriate substances and the quantities thereof which are conventionally to be used are known per se to the skilled person or may be identified by simple preliminary testing. 
Stručnjaku su poznate odgovarajuće tvari i njihove uobičajene količine koje treba primijeniti ili se mogu ustanoviti jednostavnim prethodnim pokusima.
The host cell according to claim 13, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, P3X63Ag8.653, SP2/0-Ag14, myeloma, and lymphoma cells. 
CDRH2 sekvencu amino kiseline SEK ID BR: 20; i CDRH3 sekvencu amino kiseline SEK ID BR: 44 pri čemu je, opcionalno, spomenuta stanica domaćina najmanje jedna izabrana od COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, HepG2, 653, SP2/0, 293, HeLa, mijeloma, ili stanica limfoma, ili bilo kojeg njihovog derivata, imortalizirane ili transformirane stanice.
Synthesis of compound (22) 
(22) Datum podnošenja zahtjeva u HR:
In seventh embodiment of the first aspect PG is represented by the formula: 
(33) Država ili organizacija podnošenja prve prijave: US
A method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof. 
HR P20150400 T1 PATENTNI ZAHTJEVI CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt, naznačeno time što je namijenjeno upotrebi u postupku liječenja, ublažavanja ili otklanjanja pedijatrijske akutne limfoblastične leukemije (ALL) kod pedijatrijskog pacijenta s ALL.
about 0.5% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 77% metformin hydrochloride; about 10% hydroxypropyl cellulose; about 5% microcrystalline cellulose; about 7.5% sodium starch glycolate; and about 0.6% magnesium stearate; or 
(G) 0.5% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 77% metformin hidroklorida; 10% hidroksipropil celuloze; 5% mikrokristalne celuloze; 7.5% natrijevog škrob glikolata; i 0.6% magnezijevog stearata;
A sealable container according to claim 1, wherein the base and the continuous side wall are made of a monolayer of PET. 
Posuda prema patentnom zahtjevu 2, pri čemu se osnova i kontinuirani bočni zid sastoje u osnovi od recikliranog PET-a.
The mean thickness of the lesion area was assessed in representative sections per aortic quadrant, and the statistical mean was calculated. 
Prosječna debljina područja lezije ispitana je u tipičnim odrescima po kvadrantu aorte i izračunana je statistička sredina.
Number of previous injections 
Broj međunarodne prijave:
reacting a compound of Formula (V), wherein R2a is halo, with a suitable boron species, in the presence of a palladium catalyst and a suitable base and solvent, to form a compound of Formula (II) 
reakciju spoja s formulom (V), pri čemu R2a je halo, s prikladnim boronskim vrstama, u prisutnosti paladijevog katalizatora i prikladne baze i otapala, da se dobije spoj s formulom (II) [image]
Number of units tested: 6 
Broj međunarodne objave:
A composition according to any one of the preceding claims comprising a salt of granisetron selected from the hydrochloride, mesilate, citrate, nitrate, lactate, maleate, tartrate, phosphate, succinate, fumarate and gluconate salts. 
Kompozicija prema bilo kojem od prethodnih zahtjeva, koja sadrži sol granisetrona izabranu od hidrokloridne, mezilatne, citratne, nitratne, laktatne, maleatne, tartaratne, fosfatne, sukcinatne, fumaratne i glukonatne soli.
The insulators have a thermal conductivity in g-cal/(sec) (cm²)(°C/cm), of less than about 0.05, preferably less than about 0.02, most preferably less than about 0.005. 
Izolatori imaju termičku provodijivost u g-cal/(s)(cm?)X(*C/em) manju od oko 0,05, poželjno manju od oko 0.02, najpoželjnije manju od oko 0.005.
Figure 9 is a section therethrough on the line IX-IX of Figure 8, 
je presjek limene metalne trake duž linije DX-IX iz slike 8, slika 10
Another approach is to culture cells on a packing material inside a column shaped vessel that is linked to a bioreactor (Wang et al. 1992). 
Drugi pristup je da se stanice uzgajaju na materijalu za pakiranje koji se nalazi unutar posude oblika kolone, a koja je vezana na bioreaktor (Wang i sur., 1992).
the DNA-targeting RNA, or a nucleic acid that encodes the DNA-targeting and/or 
polipeptid Cas9, ili polinukleotid koji kodira navedeni polipeptid Cas9; i/ili
It may be appropriate to administer the therapeutically effective dose as two, three, four or more sub-doses at appropriate intervals throughout the day. 
Može biti pogodno aplicirati terapijski učinkovitu dozu kao dvije, tri, četiri ili više subdoza u odgovarajućim intervalima tijekom dana.
Examples of secondary phases that can occur include, but are not limited to, alkali/earth alkali sulfates, quartzes, spinels, olivines, pyroxenes, representatives of the melilite and merwinite groups, apatites, ellestadites, silicocarnotite, free lime, spurrite, quartz and/or an x-ray amorphous phase constituent/glass phase, in a proportion of 0% by weight to 30% by weight, preferably 2% by weight to 20% by weight and especially preferred 5% by weight to 15% by weight. 
Postupak sukladno bilo kojem od zahtjeva 1 do 7, naznačen time što, uz C5925 i C4A,Fq.9)3$, klinker sadrži 0 do 30% po težini Cx(A,F(1.y)), s y opsega od 0.2 do 0.8, 0 do 20% po težini reaktivnih aluminata, 0 do 25% po težini periklasa (M), i O do 30% po težini sekundarne faze, relativno ukupnoj količini klinkera sa sadržajem sekundarne faze do 100%.
decreasing the total amount of soluble AB in the brain of an animal suffering from a disease or condition leading to increased concentrations of soluble AB in the brain; 
smanjenju ukupne količine otopinskog AB u mozgu neke životinje, posebno sisavaca, ali naročito humanog bića koje pati od bolesti ili bolesnog stanja asociranih sa amiloidom; ili
a drive mechanism for rotating said first ring member; and a coupling mechanism for releasably coupling said first ring member to said second ring member, to allow said first and second ring members to rotate cooperatively when coupled and to allow independent rotating of said first ring member when not coupled; 
pokretački mehanizam (205) za rotiranje navedenog prvog prstenastog člana; i mehanizam (700) za uparivanje za oslobađajuće uparivanje navedenog prvog prstenastog člana sa navedenim drugim prstenastim članom, da bi se omogućilo navedenom prvom i drugom prstenastom članu da se rotiraju kooperativno kada su upareni i da bi se omogućilo nezavisno rotiranje navedenog prvog prstenastog člana kada nije uparen;
The liquefied gas treatment system according to claim 2, wherein the sub LNG supply line is branched from the main LNG supply line at an upstream side of the high pressure pump. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se pomoćna linija za slanje LNG (1.24) grana od glavne linija za slanje LNG (L23) na uzvodnoj strani visokotlačne crpke (43).
The process according to claim 1, wherein the process product has a Cr(VI) content of <640 ppb. 
Postupak prema zahtjevu 1, naznačen time da proizvod iz postupka ima sadržaj Cr(VI) od < 640 ppb, poželjno < 107 ppb.
a targeter-RNA comprising a nucleotide sequence that is complementary to a target sequence of a target DNA, and 
segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna ciljanoj sekvenci u ciljanoj DNK; i
A fastening system for attaching a cover to an underground vault comprising: 
Sustav pričvršćivanja (10) za pričvršćivanje pokrova na podzemni svod sadržava:
The present disclosure relates to a freight container for transporting cargo, especially temperature sensitive cargo. 
Teretni kontejner (100) za transport tereta (5), posebno tereta osjetljivog na temperaturu, kontejner (100) sadrži:
A nucleic acid encoding a fusion protein comprising (a) a human a-N-acetylglucosaminidase (Naglu) protein comprising amino acids 24-743 of SEQ ID NO: 1, (b) an IGF-II peptide tag with at least 85% amino acid sequence identity to amino acids 8-67 of SEQ ID NO: 5, and (c) a spacer peptide located between the Naglu protein and the IGF-II peptide tag, wherein the spacer peptide comprises an amino acid sequence selected from the group consisting of 
Ciljani terapeutski fuzijski protein koji sadrži sekvencu aminokiseline koja je barem 85% identična ljudskom a-N-acetilglukozaminidaza proteinu (Naglu), peptidnu oznaku koja ima sekvencu aminokiseline koja je barem 70% identična aminokiselinama 8-67 od zrelog ljudskog IGF-II i razdvajajući peptid smješten između sekvence aminokiseline Naglu i peptidne oznake IGF-II, naznačen time da razmaknica sadrži sekvencu aminokiseline GGGGS (SEQ ID NO: 12) ili GGGPS (SEQ ID NO: 14).
Floor panel according to any of the preceding claims, characterized in that the locking element (12) is provided in a recess (13) and that, in the free noncoupled condition, it is still seated with its locking portion (17) at least partially within the recess (13). 
Podni panel prema patentnom zahtjevu 4, naznačen time što se spojni dio (50) sastoji od spojnog elementa koji se gledan u presjeku, pruža u ravnom ili otprilike ravnom smjeru i koji je u udubljenju (13).
The process of claim 1, wherein the main fuel composition and the fumigant are used for operating a compression ignition engine using the main fuel composition and the fumigant, the process further comprising: 
Postupak sukladno patentnom zahtjevu 1, naznačen time da se glavna komponenta goriva i fumigant koriste za rad motora s kompresijskim paljenjem korištenjem glavne komponente goriva i fumiganta, taj postupak nadalje obuhvaća:
According to a further feature of this aspect there is disclosed a method for providing a combined EGFR and erbB2 tyrosine kinase inhibitory effect which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore. 
Prema dodatnoj značajci ovog aspekta, objavljen je postupak koji omogućava kombinirani inhibitorni učinak na EGFR i erbB2 tirozin kinazu, koji se sastoji od davanja spomenutoj životinji efektivne doze derivata kinazolina prikazanog Formulom I, ili njegove farmaceutski prihvatljive soli, u skladu sa definicijom u gornjem tekstu.
The described compounds have a vasorelaxation effect greater than isosorbide mononitrate, and one of the compounds has a good effect compared to isosorbide dinitrate. 
Opisani spojevi imaju vazorclaksacijski učinak veći od izosorbid mononitrata, a jedan od spojeva ima dobar učinak u usporedbi s izosorbid dinitratom.
The aqueous pharmaceutical composition for use according to claim 10, 11, 12 or 13, wherein the composition further comprises excipients selected from the group consisting of zinc, m-cresol, glycerol, polysorbate 20 and sodium. 
Vodena formulacija za uporabu prema zahtjevu 22 naznačena time da navedeni farmaceutski pripravak nadalje sadrži ekscipijente odabrane iz skupine koju čine cink, m-krezol, glicerol, polisorbat 20 i natrij.
Structure according to claim 14, characterized in that the structure is provided with a sprinkler installation wherein sprinklers are located under the skylight. 
Struktura prema zahtjevu 13, naznačen time da je struktura predviđena s instalacijom raspršivača pri čemu su raspršivači smješteni ispod krovnog prozora.
The formulation of E16 or 17, wherein the surfactant is polysorbate 80. The formulation of any one of E16-18, wherein the formulation has a pH of about 5.5 to 6.5. 
Formulacija prema zahtjevu 9, naznačena time što šećer je saharoza, po izboru pri čemu surfaktant je polisorbat 80, i/ili formulacija ima pH od oko 5.5 do 6.5.
According to the second and third embodiments of the invention, the sugar replacement composition can contain four prebiotic fibres, i.e. 
Prema drugoj i trećoj varijanti ovog izuma, sastavina koja zamjenjuje šećer može sadržavati četiri vrste prebiotičkih vlakana, tj.
In specific embodiments of the present invention, the method additionally comprises another step that is carried out prior to the above-mentioned step of (increasing the) secretion of the recombinant protein in the above-mentioned medium. In said preceding step, the cells are grown in a culture medium having an osmolarity of less than 0.1 osmol/L, in particular without the above-mentioned (increase in) secretion, whereby protein accumulates in the interior or in the apoplastic space of the cells. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što, se prije navedenog koraka izlučivanja rekombinantnog proteina u navedenom mediju, stanice uzgajaju u prethodnom koraku u kultivacijskom mediju koji ima osmolarnost manju od 0,1 osmol/L, naročito bez navedenog izlučivanja, što uzrokuje nakupljanje proteina unutar stanice ili u apoplastičnom prostoru stanica.
is alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, or optionally substituted heteroaralkyl; 
je alkil, izborno supstituirani aril, izborno supstituirani heteroaril, izborno supstituirani aralkil ili izborno supstituirani heteroaralkil;
Also disclosed are compounds of Formula (Ia): wherein: 
Spoj formulo (Ia): Formula (ia) naznačen time da:
A pharmaceutical composition comprising the polymorph of any one of clauses 8-22, and a pharmaceutically acceptable carrier or diluent. 
27.Farmaceutski pripravak naznačen time da sadrži polimorf prema bilo kojem od zahtjeva 8-22, i farmaceutski prihvatljiv nosač ili dodatak za otapanje.
wherein the presence or absence of amplified DNA reflects the presence or absence, respectively, of hypermethylated target DNA in the sample. 
(c) otkrivanje prisutnosti ili odsutnosti DNA amplificirane u koraku (b), pri čemu prisutnost ili odsutnost amplificirane DNA povlači za sobom prisutnost ili odsutnost hipermetilirane ciljne DNA u uzorku.
a hair-dryer—but it is apparent for a man skilled in the art that the invention relates to other applications as well, such as to equip with a reliable GFCI a tool, a machine in a factory or any other electrical appliances. 
za sušilo za kosu - ali očito je da se za vještog čovjeka izum se odnosi ina druge primjene, kao što je opremanje pouzdanim GFCI-sklopom stroj u tvornici ili bilo koji drugi električni uređaj.
The compound, or a pharmaceutically acceptable salt thereof, of claim 5, wherein R22 is hydrogen or methyl. 
Spoj ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 5, naznačen time, da je R22 vodik ili metil.
The crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione of claim 2, wherein the X-ray powder diffraction pattern further comprises a peak at 18 degrees 2θ. 
Kristalni 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion u skladu s patentnim zahtjevom 2, naznačen time što mu uzorak difrakcije rendgenskih zraka na prahu dodatno sadrži pik na 18 stupnjeva 2θ.